Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + oxaliplatin as third-line therapy for advanced pancreatic cancer
ChiCTR2400090406Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and oxaliplatin in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Safety and Objective response rate. Started Sep 2024; status: recruiting.
02
Drugs
fluzopariboxaliplatin
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400090406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090406.